EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The emerging role of glucagon-like peptide 1 in binge eating

Katherine N Balantekin, Martin J Kretz, Elizabeth G Mietlicki-Baase iD

Journal of Endocrinology · 17.04.2024 · 262 (1)

DOI: 10.1530/joe-23-0405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, erschienen am 17.04.2024. Verfasst von Katherine N Balantekin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycemic control through its incretin effect. Additionally, the energy balance effects of GLP-1 are well-established; activation of the GLP-1 receptor (GLP-1R) reduces food intake and body weight. Aligned with these beneficial metabolic effects, there are GLP-1R agonists that are currently used for the treatment of diabetes and obesity. A growing body of literature suggests that GLP-1 may also play an important role in binge eating. Dysregulation of the endogenous GLP-1 system is associated with binge eating in non-human animal models, and GLP-1R agonists may be a promising approach to suppress the overconsumption that occurs during binge eating. Here, we briefly discuss the role of GLP-1 in normal energy intake and reward and then review the emerging evidence suggesting that disruptions to GLP-1 signaling are associated with binge eating. We also consider the potential utility of GLP-1-based pharmacotherapies for reducing binge eating behavior.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansAnimalsBinge-Eating DisorderBulimiaEnergy IntakeEnergy Metabolism

Stichwörter der Autor:innen

binge eating disorderbulimia nervosaestrogenliraglutidesemaglutide

Substanzen

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
  • Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA.

ORCID-Profile: Elizabeth G Mietlicki-Baase

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G. (2024). The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology, 262(1). https://doi.org/10.1530/joe-23-0405

Vancouver

Balantekin KN, Kretz MJ, Mietlicki-Baase EG. The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology. 2024;262(1). doi:10.1530/joe-23-0405

BibTeX
@article{Balantekin2024,
  author = {Balantekin, Katherine N and Kretz, Martin J and Mietlicki-Baase, Elizabeth G},
  title = {The emerging role of glucagon-like peptide 1 in binge eating},
  journal = {Journal of Endocrinology},
  year = {2024},
  volume = {262},
  number = {1},
  doi = {10.1530/joe-23-0405}
}
Kostenlos starten →